Camber Pharmaceuticals continues to expand its portfolio of treatment options with the launch of Sodium Oxybate Oral Solution [soe-dee-um ox-i-bate].
Sodium Oxybate Oral Solution 0.5 g/mL is available in 180 mL bottles and is indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients with narcolepsy.
Sodium Oxybate Oral Solution is a REMS product that requires distributors to be enrolled in the corresponding REMS program.
To learn more about the Sodium Oxybate REMS program, click here.
Click here to learn more about Sodium Oxybate Oral Solution
***Important Safety Information for Sodium Oxybate Oral Solution***
Sodium Oxybate Oral Solution carries a boxed warning for central nervous system (CNS) depression and abuse and misuse. Taking Sodium Oxybate with other Central Nervous System (CNS) depressants has been associated with trouble breathing (respiratory depression), low blood pressure (hypotension), changes in alertness (drowsiness), fainting (syncope), and death.
Sodium Oxybate is a form of gamma hydroxybutyrate (GHB). Abuse or misuse of illegal GHB alone or with other CNS depressants (drugs that cause changes in alertness or consciousness) may result in seizures, trouble breathing (respiratory depression), changes in alertness (drowsiness), coma, and death. Patients on Sodium Oxybate should be monitored for confusion, anxiety, and suicidality.
Because of these risks, Camber Pharmaceuticals’ Sodium Oxybate is available only through the shared Sodium Oxybate REMS Program. Patients must be enrolled in the shared Sodium Oxybate REMS Program to receive Camber Pharmaceuticals’ Sodium Oxybate Oral Solution.
